US › Healthcare

Quoin Pharmaceuticals Ltd DRC (QNRX)

US · Healthcare · Biotechnology

$4.35-2.25%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-5.0M
Profit YoY
-30.7%
EPS
$-1.77
EPS estimate
$-2.26

EPS came in at -1.77 against a street estimate of -2.26 — a beat of 21.7%.

Key statistics

Market cap
$8.9M
Forward P/E
0.0
P/B
1.02
Book value
$4.47
EPS (TTM)
$-10.07
52-week high
$23.50
52-week low
$3.25
50-day MA
$4.50
200-day MA
$8.83
Beta
1.66

Analyst view

Analysts rate Quoin Pharmaceuticals Ltd DRC a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $21.40.

Shareholding

Insiders
2.63%
Institutions
52.52%

Largest institutional holders

FundStake
Ikarian Capital, LLC14.12%
Dauntless Investment Group, LLC13.12%
SummitTX Capital, L.P6.69%
Velan Capital Investment Management LP5.66%
Woodline Partners LP5.31%
Millennium Management LLC5.09%
Aberdeen Group PLC5.01%
Soleus Capital Management, L.P.4.85%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Quoin Pharmaceuticals Ltd DRC — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.